25 August 2016
CHRIS GALLAHER ELECTED AS NEW CHAIRMAN FOR PACIFIC EDGE BOARD
The Board of cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has
announced the election of Mr Chris Gallaher as Chairman, replacing Mr Chris
Swann who, as previously advised, is stepping down from the Board at today''s
Annual Shareholders'' Meeting.
Chris Gallaher was appointed to the Pacific Edge Board in July 2016. He is an
internationally experienced senior executive, with significant financial and
risk management expertise. He has held a number of senior roles, including
CEO of Village Roadshow and most recently as Group Chief Financial Officer of
Fulton Hogan.
Mr Gallaher said he was looking forward to stepping into the role. "Pacific
Edge is an exciting company with world leading products. It has positioned
itself well to win in the world''s largest healthcare market, the USA, and is
gaining good traction in other markets. The company has enormous potential
and is creating significant value, both for society through better health
outcomes, and for our shareholders. The task for the company is to continue
its growth and its delivery of that potential."
Pacific Edge would like to acknowledge the contribution made by Chris Swann
during his 11 years on the Board. During his tenure, Pacific Edge has evolved
from a research organisation to a commercial entity, with a well-developed
commercial strategy, market operations in New Zealand, Australia and the USA
and a ''one stop shop'' of bladder cancer diagnostic products.
Mr Swann said: "I have been privileged to be part of Pacific Edge''s journey
as we have grown and built our international business. Pacific Edge is
leading the way in molecular diagnostics for bladder cancer patients, and we
are now seeing growing acceptance and demand for our easy to use, accurate
and cost effective Cxbladder tests. I leave Pacific Edge knowing that it is
in good hands, with a strong Board and an experienced and highly capable
executive team."
ENDS
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company''s products have been tested and
validated in international multi-centre clinical studies.
Pacific Edge has three proprietary, novel, accurate, molecular diagnostic
products in-market providing actionable results, and better detection and
management of urothelial cancer. Cxbladder Detect is available through the
company''s dedicated CLIA certified laboratories for customers in New Zealand,
Australia and the USA. Cxbladder Triage is available in New Zealand and
Australia. Cxbladder Monitor launched in New Zealand in December 2015 and is
anticipated being available in the US in 2016.
ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional
phenotypic and clinical risk factors to accurately identify patients with
haematuria who have a low probability of bladder cancer and may not require a
more extensive urological evaluation. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation of patients with hematuria
and is intended to reduce the need for an expensive and invasive work-up in
patients who have a low probability of having urothelial carcinoma.
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients'' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company''s CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.
ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists,
is a proprietary, non-invasive, molecular diagnostic test that combines
genomic biomarkers measured from a small quantity of a patient''s urine, with
patient specific clinical factors to better monitor bladder cancer patients
for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires
life-long surveillance. Cxbladder Monitor accurately identifies patients with
a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows
that they have a low probability of recurrent urothelial carcinoma. Cxbladder
Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder
cancer.
Refer to www.cxbladder.com for more information.
End CA:00287891 For:PEB Type:OFFICE Time:2016-08-25 14:33:45